A drug associated with lung injury and uses thereof

By using gabapentin to reduce MPO and NOX2 levels in lung tissue, the problems of oxidative stress and inflammation in lung interruption and re-inhalation injury were resolved, achieving protection and functional recovery of lung tissue.

CN122297451APending Publication Date: 2026-06-30NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV
Filing Date
2026-05-06
Publication Date
2026-06-30

AI Technical Summary

Technical Problem

Lung interruption and re-inflation injury during thoracic surgery leads to oxidative stress and inflammatory response in lung tissue, and current technology lacks effective drug prevention or treatment methods.

Method used

Gabapentin or its pharmaceutically acceptable salts are prepared into oral or injectable formulations to treat and prevent lung decompression and rebreathing injury by reducing MPO and NOX2 levels in lung tissue.

Benefits of technology

It significantly reduces MPO and NOX2 levels in damaged lung tissue, decreases neutrophil infiltration and reactive oxygen species production, inhibits inflammatory response, protects the pulmonary vascular endothelial barrier function, reduces pulmonary edema, and treats and prevents lung interruption and re-ventilation injury.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122297451A_ABST
    Figure CN122297451A_ABST
Patent Text Reader

Abstract

This invention provides a drug related to lung injury and its application, the drug comprising gabapentin and / or pharmaceutically acceptable salts of gabapentin; the drug reduces the levels of MPO and NOX2 in lung tissue; the application is for the preparation of formulations for the prevention or treatment of lung injury using gabapentin and / or pharmaceutically acceptable salts of gabapentin, or for the study of the mechanism of lung injury caused by surgery; the study is related to manufacturing and application in industry; the drug can prevent or treat damage caused by lung interruption and re-inflation during lung surgery, and has good application prospects in industry.
Need to check novelty before this filing date? Find Prior Art